What We're Reading: Page 381
Industry reads hand-picked by our editors
Mar 20, 2015
Mar 19, 2015
-
ABC News
AbbVie seeks $30 million expansion in Puerto Rico
-
Science Blogs
Scientists slam NYT article warning of Apple Watch cancer risks
-
Bloomberg
Former Salix execs who left under controversy nab big golden parachutes
-
Reuters
Sanofi research head: Global drug regulation rifts hurting biopharma
-
FiercePharma
Outgoing Bristol-Myers chief walking out with $27 million
Mar 18, 2015
-
FiercePharma Marketing
Mango Health launching Rx adherence app for Apple Watch
-
Irish Times
AstraZeneca COPD blockbuster candidate shines in trial
-
Xconomy
Retrophin nabs new drug, priority review voucher
-
The Japan News
Doc admits to falsifying Diovan data
-
Pharma Times
Australian pharma lobbies for better cancer drug approval process
Mar 17, 2015
-
Reuters
Study says pricey Gilead hep C drugs are cost-effective—but what does that mean?
-
FierceBiotech
Glaxo, J&J back $100M Alzheimer's R&D project
-
Reuters
Esperion cholesterol med bests statins in trial
-
Wall Street Journal
Obesity drugs like Saxenda a hard sell to patients, docs
-
Reuters
WHO: Superbug TB strains 'ravaging' Europe
Mar 16, 2015
-
Pharma Times
FDA expands use of Actavis bipolar drug to children
-
FierceBiotech
Cidara jumps into the IPO queue
-
FiercePharma Asia
China drug approval backlog swells
-
Pharmaceutical Business Review
Baxter hemophilia drug comes through in phase III
Mar 13, 2015
Mar 12, 2015
-
Bloomberg
23andMe to expand from genetic testing to new drug development
-
The Street
Acadia CEO to retire as Parkinson's drug is delayed again
-
FiercePharma
Teva probably won't buy Mylan—but should it?
-
Reuters
CVS: Biosimilars could cut prices in half
-
Medical Marketing & Media
Open Payments glitches inhibit pharma, device maker submissions
Previous
